 Sai-Hong Ignatius Ou
|
|
| Title(s) | Health Sciences Professor, Medicine |
|---|
| Phone | (714) 456-5153 |
|---|
| vCard | Download vCard |
|---|
|
|
 Bibliographic
-
Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 Jan; 139:22-27. PMID: 31706099.
-
Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 01; 12(1):145-151. PMID: 27697581.
-
Ou SH, Pasi J. Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al. Ann Oncol. 2014 Oct; 25(10):2093. PMID: 25035278.
-
Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol. 2012 Sep; 83(3):407-21. PMID: 22257651.
-
Ou SI, Zell JA. The effect of tumor size on non-size-based descriptors in staging of stage I non-small cell lung cancer. Chest. 2009 Jun; 135(6):1695-1696. PMID: 19497911.
|
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|